Roth Capital Affirms Peregrine Pharma (PPHM) at 'Buy'; Remains Encouraged by Progress in FY14
Tweet Send to a Friend
Roth Capital affirms its Buy rating and $5 price target on Peregrine Pharmaceuticals (Nasdaq: PPHM) following Q2 results issued after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
